Improvement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosis.

Q: What does this research mean for the field?

Treatment with resmetirom improves disease-specific health-related quality of life scores in patients with early MASH and MASH cirrhosis. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

Zobair M Younossi; FATEMA NADER; Dominic Labriola; Rebecca Taub; Andrei Racila; Linda Henry; Maria Stepanova

doi:10.1097/hc9.0000000000000913

March 1, 2026

Improvement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosis.

View Full Paper

Ask AI

Bookmark

Share

Key Points

To assess the impact of resmetirom on health-related quality of life in patients with early MASH and MASH cirrhosis.
Analyzed health-related quality of life scores before and after resmetirom treatment.
Included patients across the spectrum of MAFLD from early MASH to MASH cirrhosis.
Evaluated disease-specific outcomes.
Patients experienced significant improvements in certain disease-specific HRQL scores after treatment with resmetirom.

Implication

Clinical trial reveals improved health-related quality of life scores in patients with MASH, indicating potential benefits of resmetirom treatment.

Abstract

Early MASH and MASH cirrhosis treated with resmetirom experience improvement in some disease-specific HRQL scores.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Younossi et al. (2026) studied this question.

synapsesocial.com/papers/69a3d800ec16d51705d2e7e1 https://doi.org/10.1097/hc9.0000000000000913

View Full Paper

Ask AI

Bookmark

Share

Improvement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosis.

Key Points

Implication

Abstract

Discussion

Cite This Study

Improvement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosis.

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading